Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Receivables - Net of $40.0 million for Q2 2025, up 2247.42% year-over-year from $1.7 million in Q2 2024, and up 100.0% quarter-over-quarter from $20.0 million in Q1 2025.
Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Receivables - Net for 6 consecutive years, with $40.0 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Receivables - Net rose 2247.42% year-over-year to $40.0 million; the TTM figure through Jun 2025 stood at $40.0 million (up 2247.42% YoY), while the FY2024 annual figure was $947000.0, down 94.95% from the prior year.
- Receivables - Net climbed to $40.0 million in Q2 2025 per KYMR's latest filing, from $20.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $40.0 million in Q2 2025 and bottomed at $135000.0 in Q4 2021.
- Historically, Receivables - Net has averaged $6.1 million across 5 years, with a median of $2.2 million in 2022.
- Annual changes were most pronounced in 2024 — Receivables - Net sank 94.95% — and 2025, when it jumped 2247.42%.
- Kymera Therapeutics' Receivables - Net stood at $135000.0 in 2021, then soared by 1779.26% to $2.5 million in 2022, then soared by 639.53% to $18.8 million in 2023, then tumbled by 94.95% to $947000.0 in 2024, then soared by 4123.86% to $40.0 million in 2025.
- Business Quant data shows KYMR's Receivables - Net at $40.0 million in Q2 2025, $20.0 million in Q1 2025, and $947000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.00 Mn |
| Jun 30, 2026 | 20.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | 20.00 Mn |
| Mar 31, 2025 | 20.00 Mn |
| Dec 31, 2024 | 947,000.00 |
| Dec 31, 2024 | 947,000.00 |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | 18.76 Mn |
| Dec 31, 2023 | 18.76 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Sep 30, 2023 | 3.78 Mn |
| Jun 30, 2023 | 4.12 Mn |
| Jun 30, 2023 | 4.12 Mn |